The effect of anticoagulants and the role of thrombin on neutrophil-endothelial cell interactions in septic SHOCK

Shock

Volumn 31, Issue 2, 2009, Pages 120-124

  Tsen, Anita ^a,b   Kirschenbaum, Linda A ^a,b,c   Larow, Catherine ^a,b   Khan, Raymond ^a,b   Kurtz, Susannah ^a,b   Bansal, Sandeep ^a,b   Astiz, Mark E ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ST VINCENT S HOSPITAL   (United States)

^c ST VINCENT S HOSPITAL MANHATTAN   (United States)

Author keywords

Activated protein c; Antithrombin iii; Argatroban; Endothelium, neutrophil; Platelet, heparin; Septic; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; ARGATROBAN; DROTRECOGIN; HEPARIN; THROMBIN;

ADULT; AGED; ARTICLE; CELL ADHESION; CELL AGGREGATION; CELL INTERACTION; CELL SUSPENSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; NEUTROPHIL; PHASE CONTRAST MICROSCOPE; PLASMA; SEPTIC SHOCK; THROMBOCYTE; THROMBOCYTE ACTIVATION; UMBILICAL VEIN;

AGED; ANTICOAGULANTS; BLOOD PLATELETS; CELL ADHESION; ENDOTHELIAL CELLS; FLOW CYTOMETRY; HEPARIN; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; NEUTROPHILS; PROTEIN C; SEPSIS; SHOCK, SEPTIC; THROMBIN;

EID: 59649108575     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318180ffe9     Document Type: Article

References (38)

1. Lam C, Tyml K, Martin C, Sibbald WJ: Microvascular perfusion is impaired in a rat model of normotensive sepsis. J Clin Invest 94:2077-2083, 1994.
2. Astiz ME, DeGent G, Rackow EC: Microvascular function and rheologic changes in hyperdynamic sepsis. Crit Care Med 23:265-271, 1995.
3. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL: Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166: 98-104, 2002.
4. Esmon C: The interactions between inflammation and coagulation. Br J Haematol 131:417-430, 2005.
5. Opal S: Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 28:77-81, 2000.
6. Chu A: Tissue factor mediates inflammation. Arch Biochem Biophys 440: 123-132, 2005.
7. Coughlin SR: Thrombin signaling and protease-activated receptors. Nature 407:258-264, 2000.
8. Kirchhofer D, Sakariassen KS, Clozel M, Tschopp TB, Hadvary P, Nemerson Y, Baumgartner HR: Relationship between tissue factor expression and deposition of fibrin, platelets, and leukocytes on cultured endothelial cells under venous blood flow conditions. Blood 81:2050-2058, 1993.
9. Uchiba M, Okajima K, Murakami K: Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities. Thromb Res 89:233-242, 1998.
10. Eriksson M, Basu S, Larsson A, Mattsson C, Eriksson O, Kiiski R, Nordgren A: Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. Expert Opin Investig Drugs 9:1129-1137, 2000.
11. Filkins J, Luzio N: Heparin protection in endotoxin shock. Am J Physiol 214:1074-1077, 1968.
12. Dickneite G, Czech J: Combination of antibiotic treatment with thrombin inhibitor recombinant hirudin for the therapy of experimental Klebsiella pneumonia sepsis. Thromb Haemost 71:768-772, 1994.
13. Schiffer ER, Reber G, Moerloose P, Morel DR: Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. Crit Care Med 30:2689-2699, 2002.
14. Meyer J, Cox C, Herndon D, Nakazawa H, Lentz CW, Traber LD, Traber DL: Heparin in experimental hyperdynamic sepsis. Crit Care Med 21:84-89, 1993.
15. Taylor FB, Emerson T, Jordan R, Chang AK, Blick KE: Antithrombin III prevents the lethal effects of E. coli infusion in baboons. Circ Shock 26:227-235, 1988.
16. Taylor FB, Chang A, Esmon C, D'Angelo A, Vigano-D'Angelo S, Blick KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79:918-925, 1987.
17. Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: for The Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709, 2001.
18. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, et al.: for the KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869-1878, 2001.
19. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez A-L, Beale R, Svoboda P, Laterre PF, Simon S, et al.: for the OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 390:238-247, 2003.
20. Hoffman JN, Vollmar B, Laschke MW, Inthom D, Fertmann J, Schildberg FW, Menger MD: Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 32:1011-1017, 2004.
21. Kirschenbaum L, Correa Lopez W, Ohrum P, Tsen A, Khazin J, Astiz ME: Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions septic shock. Crit Care Med 34: 2207-2212, 2006.
22. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y: Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 33: 368-372, 2005.
23. Kirschenbaum LA, McKevitt D, Rullan M, Reisbeck B, Fujii T, Astiz ME: Importance of platelets and fibrinogen in neutrophil-endothelial cell interactions in septic shock. Crit Care Med 32:1904-1909, 2004.
24. Macias W, Dhainaut J, Yan SC, Helterbrand JD, Seger M, Johnson G 3rd, Small DS: Pharmokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 72:391-402, 2002.
25. Stone P, Nash GB: Conditions under which immobilized platelets activate as well as capture flowing neutrophils. Br J Haematol 105:514-522, 1999.
26. Kaplanski G, Fabriqoule M, Boulay V, Dinerello CA, Bongrand P, Kaplanski S, Farnarier C: Thrombin induces endothelial type II activation in vitro: IL-1 and TNF-alpha-independent IL-secretion and E-selectin expression. J Immunol 158:5435-5441, 1997.
27. Renckens R, Roelofs JJ, ter Horst SA, van't Veer C, Havik SR, Florquin S, Wagenaar GT, Meijers JC, van der Poll T: Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 175:6764-6771, 2005.
28. Dhainaut J, Yan S, Margolis BD, Lorente JA, Russell JA, Freebaim RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, et al.: PROWESS Sepsis Study Group: Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 90:642-653, 2003.
29. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemond J: Double-blind placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882-888, 1993.
30. Kountchev J, Bijuklic K, Bellmann R, Wiedemann CJ, Joannidid M: Reduction of D-dimer levels after therapeutic administration of antithrombin III in acquired antithrombin deficiency of severe sepsis. Crit Care 9: R596-R600, 2005.
31. Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD: Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Cell Physiol 279:C98-C107, 2000.
32. Woodman R, Teoh D, Payne D, Kubes P: Thrombin and leukocyte recruitment in endotoxemia. Am J Physiol Heart Circ Physiol 279:H1338-H1345, 2000.
33. Hoffmann JN, Vollmar B, Inthom D, Schildberg FW, Menger MD: The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/ endothelial cell interaction and microvascular perfusion failure. Shock 14: 528-534, 2000.
34. Murakami K, Okajima K, Uchiba M, Johno M, Nagakaki T, Okabe H, Takatsuki K: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 87:642-647, 1996.
35. Opal S, Kessler CM, Roemisch J, Knaub S: Antithrombin, heparin and heparan sulfate. Crit Care Med 30(suppl):S325-S331, 2002.
36. Mosnier L, Ziokovic B, Griffen J: The cytoprotective protein C pathway. Blood 109:3161-3172, 2007.
37. De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL: Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 34:1918-1924, 2006.
38. Taylor F, Chang A, Peer GT, Mather T, Blick K, Catlett R, Lockhart MS, Esmon CT: DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 78:364-368, 1991.